TP53 and acute myeloid leukemia: Finally, we observe that primary AML patient cells are highly sensitive to USP7 inhibition, also in poor prognosis patients carrying TP53 mutations, indicating that USP7 inhibition could be an attractive alternative therapy for treatment of AML patients.